248 related articles for article (PubMed ID: 35841781)
41. Molecular Binding Mechanism and Pharmacology Comparative Analysis of Noscapine for Repurposing against SARS-CoV-2 Protease.
Kumar N; Sood D; van der Spek PJ; Sharma HS; Chandra R
J Proteome Res; 2020 Nov; 19(11):4678-4689. PubMed ID: 32786685
[TBL] [Abstract][Full Text] [Related]
42. Gene signatures and potential therapeutic targets of Middle East respiratory syndrome coronavirus (MERS-CoV)-infected human lung adenocarcinoma epithelial cells.
Wu YH; Yeh IJ; Phan NN; Yen MC; Hung JH; Chiao CC; Chen CF; Sun Z; Hsu HP; Wang CY; Lai MD
J Microbiol Immunol Infect; 2021 Oct; 54(5):845-857. PubMed ID: 34176764
[TBL] [Abstract][Full Text] [Related]
43. Transcriptomic analysis reveals novel mechanisms of SARS-CoV-2 infection in human lung cells.
Yang S; Wu S; Yu Z; Huang J; Zhong X; Liu X; Zhu H; Xiao L; Deng Q; Sun W
Immun Inflamm Dis; 2020 Dec; 8(4):753-762. PubMed ID: 33124193
[TBL] [Abstract][Full Text] [Related]
44. Oxytocin's anti-inflammatory and proimmune functions in COVID-19: a transcriptomic signature-based approach.
Imami AS; O'Donovan SM; Creeden JF; Wu X; Eby H; McCullumsmith CB; Uvnäs-Moberg K; McCullumsmith RE; Andari E
Physiol Genomics; 2020 Sep; 52(9):401-407. PubMed ID: 32809918
[TBL] [Abstract][Full Text] [Related]
45. Remdesivir against COVID-19 and Other Viral Diseases.
Malin JJ; Suárez I; Priesner V; Fätkenheuer G; Rybniker J
Clin Microbiol Rev; 2020 Dec; 34(1):. PubMed ID: 33055231
[TBL] [Abstract][Full Text] [Related]
46. Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines.
Lambert PH; Ambrosino DM; Andersen SR; Baric RS; Black SB; Chen RT; Dekker CL; Didierlaurent AM; Graham BS; Martin SD; Molrine DC; Perlman S; Picard-Fraser PA; Pollard AJ; Qin C; Subbarao K; Cramer JP
Vaccine; 2020 Jun; 38(31):4783-4791. PubMed ID: 32507409
[TBL] [Abstract][Full Text] [Related]
47. [Diagnosis, treatment, control and prevention of SARS-CoV-2 and coronavirus disease 2019: back to the future].
Ye ZW; Jin DY
Sheng Wu Gong Cheng Xue Bao; 2020 Apr; 36(4):571-592. PubMed ID: 32347053
[TBL] [Abstract][Full Text] [Related]
48. Structure-activity relationship (SAR) and molecular dynamics study of withaferin-A fragment derivatives as potential therapeutic lead against main protease (M
Ghosh A; Chakraborty M; Chandra A; Alam MP
J Mol Model; 2021 Feb; 27(3):97. PubMed ID: 33641023
[TBL] [Abstract][Full Text] [Related]
49. CCR2 Signaling Restricts SARS-CoV-2 Infection.
Vanderheiden A; Thomas J; Soung AL; Davis-Gardner ME; Floyd K; Jin F; Cowan DA; Pellegrini K; Shi PY; Grakoui A; Klein RS; Bosinger SE; Kohlmeier JE; Menachery VD; Suthar MS
mBio; 2021 Dec; 12(6):e0274921. PubMed ID: 34749524
[TBL] [Abstract][Full Text] [Related]
50. The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.
Chaccour C; Ruiz-Castillo P; Richardson MA; Moncunill G; Casellas A; Carmona-Torre F; Giráldez M; Mota JS; Yuste JR; Azanza JR; Fernández M; Reina G; Dobaño C; Brew J; Sadaba B; Hammann F; Rabinovich R
Trials; 2020 Jun; 21(1):498. PubMed ID: 32513289
[TBL] [Abstract][Full Text] [Related]
51. COVID-19 pandemic: A multidisciplinary perspective on the pathogenesis of a novel coronavirus from infection, immunity and pathological responses.
Yi J; Miao J; Zuo Q; Owusu F; Dong Q; Lin P; Wang Q; Gao R; Kong X; Yang L
Front Immunol; 2022; 13():978619. PubMed ID: 36091053
[TBL] [Abstract][Full Text] [Related]
52. Weighted Gene Co-Expression Network Analysis Combined with Machine Learning Validation to Identify Key Modules and Hub Genes Associated with SARS-CoV-2 Infection.
Karami H; Derakhshani A; Ghasemigol M; Fereidouni M; Miri-Moghaddam E; Baradaran B; Tabrizi NJ; Najafi S; Solimando AG; Marsh LM; Silvestris N; De Summa S; Paradiso AV; Racanelli V; Safarpour H
J Clin Med; 2021 Aug; 10(16):. PubMed ID: 34441862
[TBL] [Abstract][Full Text] [Related]
53. Identifying Transcriptomic Signatures and Rules for SARS-CoV-2 Infection.
Zhang YH; Li H; Zeng T; Chen L; Li Z; Huang T; Cai YD
Front Cell Dev Biol; 2020; 8():627302. PubMed ID: 33505977
[TBL] [Abstract][Full Text] [Related]
54. Cytotoxic CD8-positive T-lymphocyte infiltration in the lungs as a histological pattern of SARS-CoV-2 pneumonitis.
Puzyrenko A; Felix JC; Ledeboer NA; Sun Y; Rui H; Sheinin Y
Pathology; 2022 Jun; 54(4):404-408. PubMed ID: 34836647
[TBL] [Abstract][Full Text] [Related]
55. Antiviral and Immunomodulatory Effects of
Papies J; Emanuel J; Heinemann N; Kulić Ž; Schroeder S; Tenner B; Lehner MD; Seifert G; Müller MA
Front Pharmacol; 2021; 12():757666. PubMed ID: 34759825
[TBL] [Abstract][Full Text] [Related]
56. Attenuation of clinical and immunological outcomes during SARS-CoV-2 infection by ivermectin.
de Melo GD; Lazarini F; Larrous F; Feige L; Kornobis E; Levallois S; Marchio A; Kergoat L; Hardy D; Cokelaer T; Pineau P; Lecuit M; Lledo PM; Changeux JP; Bourhy H
EMBO Mol Med; 2021 Aug; 13(8):e14122. PubMed ID: 34170074
[TBL] [Abstract][Full Text] [Related]
57. Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: a global perspective.
Halawa S; Pullamsetti SS; Bangham CRM; Stenmark KR; Dorfmüller P; Frid MG; Butrous G; Morrell NW; de Jesus Perez VA; Stuart DI; O'Gallagher K; Shah AM; Aguib Y; Yacoub MH
Nat Rev Cardiol; 2022 May; 19(5):314-331. PubMed ID: 34873286
[TBL] [Abstract][Full Text] [Related]
58. Time-series bioinformatics analysis of SARS-CoV-infected cells to identify the biological processes associated with severe acute respiratory syndrome.
Fatehi R; Khosravian F; Salehi M; Kazemi M
Hum Antibodies; 2023; 31(4):81-88. PubMed ID: 38143341
[TBL] [Abstract][Full Text] [Related]
59. A differential regulatory T cell signature distinguishes the immune landscape of COVID-19 hospitalized patients from those hospitalized with other respiratory viral infections.
Vick SC; Frutoso M; Mair F; Konecny AJ; Greene E; Wolf CR; Logue JK; Boonyaratanakornkit J; Gottardo R; Schiffer JT; Chu HY; Prlic M; Lund JM
medRxiv; 2021 Mar; ():. PubMed ID: 33791720
[TBL] [Abstract][Full Text] [Related]
60. Assessment of Purity, Stability, and Pharmacokinetics of NGP-1, a Novel Prodrug of GS441254 with Potential Anti-SARS-CoV-2 Activity, Using Liquid Chromatography.
Sun C; Liu B; Zhou F; Zheng Q; Dai C; Wei W; Liao G; Sun Y
Molecules; 2023 Jul; 28(15):. PubMed ID: 37570604
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
